Diversified Trust Co Sells 6,271 Shares of Globus Medical, Inc. $GMED

Diversified Trust Co trimmed its stake in Globus Medical, Inc. (NYSE:GMED) by 40.7% during the first quarter, Holdings Channel reports. The fund owned 9,140 shares of the medical device company’s stock after selling 6,271 shares during the period. Diversified Trust Co’s holdings in Globus Medical were worth $788,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of GMED. SBI Securities Co. Ltd. increased its stake in shares of Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after purchasing an additional 167 shares during the last quarter. Advisory Services Network LLC bought a new stake in shares of Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. Larson Financial Group LLC lifted its stake in Globus Medical by 83.4% in the fourth quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 242 shares during the last quarter. Finally, Parallel Advisors LLC lifted its stake in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research lifted multiple earnings forecasts for Globus Medical, signaling improving expectations for future profitability and supporting the stock. Globus Medical stock page
• Positive Sentiment: The analyst firm reiterated a Strong-Buy rating, which may reinforce investor confidence in GMED. Globus Medical stock page
• Neutral Sentiment: One article discussed large executive and median employee pay increases in 2025, which could draw attention to compensation practices but does not appear to be a major operating update. Globus Medical compensation article
• Neutral Sentiment: Another article framed the company’s prior earnings beat and foreign exchange pressures as factors that may affect the investment case, but it did not introduce a fresh negative catalyst. Globus Medical earnings/FX article

Globus Medical Price Performance

NYSE:GMED opened at $82.37 on Thursday. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The stock’s fifty day moving average price is $83.95 and its two-hundred day moving average price is $87.47. The company has a market cap of $11.18 billion, a P/E ratio of 19.16, a P/E/G ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the previous year, the business earned $0.68 earnings per share. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director owned 510,175 shares of the company’s stock, valued at $41,201,733. The trade was a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 18.38% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have issued reports on GMED. Needham & Company LLC raised their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Truist Financial set a $115.00 price target on Globus Medical in a research note on Wednesday, February 25th. Royal Bank Of Canada lifted their price objective on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Finally, Wells Fargo & Company lowered their price objective on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Globus Medical has an average rating of “Moderate Buy” and an average target price of $105.00.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.